Referências
ACOG. Committee Opinion No. 638: First-Trimester Risk Assessment for Early-Onset Preeclampsia. Obstet Gynecol, 2015 Sep;126(3):e25-7. doi: 10.1097/AOG.0000000000001049.
Dadelszen P, Magee LA. Preventing deaths due to the hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol. 2016; 36: 83-102. Doi: 10.1016/j.bpobgyn.2016.05.005
O’Gorman N, Wright D, Syngelaki A, et al. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation. Am J Obstet Gynecol. 2016;214(1):103.e1-103.e12. Doi: 10.1016/j.ajog.2015.08.034.
Poon LCY, Kametas NA, Chelemen T, Leal A, Nicolaides KH. Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach. Journal of Human Hypertension; 2010; 104-110.
Ramos JGL, Sass N, Costa SHM. Pré-eclâmpsia. Rev. Bras. Ginecol. Obstet. [online]; 2017; 39(9): 496-512. Doi: https://doi.org/ 10.1055/s-0037-1604471.
Roberge S, Demers S, Nicolaides KH, Bureau M, Côté S, Bujold E. Prevention of pre-eclampsia by low-molecular-weight heparin in addition to aspirin: a meta-analysis. Ultrasound Obstet Gynecol. 2016;47(5):548-53. Doi: 10.1002/uog.15789.
Rocha RS, Alves JAG, Maia E Holanda Moura SB, et al. Simple approach based on maternal characteristics and mean arterial pressure for the prediction of preeclampsia in the first trimester of pregnancy. J Perinat Med. 2017;45(7):843-849. Doi: 10.1515/jpm-2016-0418.
Traquilli AL, Dekker G, Magee L, Roberts J, Sibai BM, et al. The Classification, Diagnosis and Management of the Hypertensive Disorders of Pregnancy: A Revised Statement From the ISSHP. Pregnancy Hypertens. 2014 Apr; 4(2):97-104. Doi: 10.1016/j.preghy.2014.02.001.
Wright D, Syngelaki A, Akolekar R, Poon LC, Nicolaides KH. Competing Risks Model in Screening for Preeclampsia by Maternal Characteristics and Medical History. Am J Obstet Gynecol. 2015 Jul;213(1):62.e1-62.e10. Doi: 10.1016/j.ajog.2015.02.018.
Costantine MM, Cleary K, Hebert MF; et al. Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial. Am J Obstet Gynecol. 2016;214(6):720.e1-720.e17. Doi: 10.1016/j.ajog.2015.12.038.
Rolnik DL, Wright D, Poon LC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377(7):613-622. Doi: 10.1056/NEJMoa1704559.
Talari H, Mesdaghinia E, Abedzadeh Kalahroudi M. Aspirin and preeclampsia prevention in patients with abnormal uterine artery blood flow. Iran Red Crescent Med J. 2014;16(8):e17175. Doi:10.5812/ircmj.17175.
Camarena Pulido EE, García Benavides L, Panduro Barón JG, et al. Efficacy of L-arginine for preventing preeclampsia in high-risk pregnancies: a double-blind, randomized, clinical trial. Hypertens Pregnancy. 2016;35(2):217-25. Doi: 10.3109/10641955.2015.1137586.
Hofmeyr GJ, Belizán JM, von Dadelszen P, Calcium and Pre-eclampsia (CAP) Study Group. Low-dose calcium supplementation for preventing pre-eclampsia: a systematic review and commentary. BJOG. 2014;121(8):951–957. Doi:10.1111/1471-0528.12613.
Souza EV, Torloni MR, Atallah AN, Santos GMS, Kulay Jr L, Sass N. Aspirin plus calcium supplementation to prevent superimposed preeclampsia: a randomized trial. Braz J Med Biol Res. 2014;47(5): 419-425. Doi: http://dx.doi.org/10.1590/1414-431X20143629.
Parrish MR, Martin JN Jr, Lamarca BB, et al. Randomized, placebo controlled, double blind trial evaluating early pregnancy phytonutrient supplementation in the prevention of preeclampsia. J Perinatol. 2013;33(8):593-9. Doi: 10.1038/jp.2013.18.
Roberge S, Bujold E, Nicolaides KH. Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis. Am J Obstet Gynecol. 2018;218(3):287-293.e1. Doi: 10.1016/j.ajog.2017.11.561.
Roberge S, Nicolaides K, Demers S, Hyett J, Chaillet N, Bujold E. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol. 2017;216(2):110-120.e6. Doi: 10.1016/j.ajog.2016.09.076.
Roberge S, Demers S, Nicolaides KH, Bureau M, Côté S, Bujold E. Prevention of pre-eclampsia by low-molecular-weight heparin in addition to aspirin: a meta-analysis. Ultrasound Obstet Gynecol. 2016;47(5):548-53. Doi: 10.1002/uog.15789.
Gan J, He H, Qi H. Preventing preeclampsia and its fetal complications with low-dose aspirin in East Asians and non-East Asians: a systematic review and meta-analysis. Hypertens Pregnancy. 2016;35(3):426-35. doi: 10.1080/10641955.2016.1178772.
Rodger MA, Carrier M, Le Gal G, et al. Meta-analysis of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications. Blood. 2014;123(6):822-8. Doi: 10.1182/blood-2013-01-478958.
Costantine MM, Ananth CV. The early developments of preeclampsia drugs. Expert Opin Investig Drugs. 2016;25(8):867–870. Doi:10.1080/13543784.2016.1196185.